Abstract

Formulation and characterization of Luliconazole (LZL) nanosuspensions using modified starch ester polymer to increase solubility. X-ray analysis of A6 and B4 lyophilized nanosuspensions confirmed amorphous nature having % relative crytalinilty of 48.453, 41.374% and crystallite size of 21 and 35 nm; respectively. However, solubility of lyophilized nanosuspension improved by more than 370 fold in comparison to that of pure LZL-API which brings it in soluble form at pH-1.2. In-vitro antifungal studies revealed that lyophilized nanosuspension enhanced activity against fungi yeasts (Candida albican, Candida auris) and Aspergillus (A. Flavus, A. Nigar) when compared to LZL marketed cream.

摘要

使用改性淀粉酯聚合物增加溶解度的卢立康唑 (LZL) 纳米混悬剂的配方和表征。A6 和 B4 冻干纳米混悬液的 X 射线分析证实了无定形性质，具有 48.453、41.374% 的相对结晶度和 21 和 35 nm 的微晶尺寸；分别。然而，与纯 LZL-API 相比，冻干纳米混悬剂的溶解度提高了 370 倍以上，使其在 pH-1.2 下呈可溶形式。体外抗真菌研究表明，与 LZL 上市的乳膏相比，冻干纳米混悬剂增强了对真菌酵母（白色念珠菌、耳念珠菌）和曲霉（A. Flavus、A. Nigar ）的活性。